Eviction and the Necessary Conditions for Health | NEJM
Perspective from The New England Journal of Medicine — Eviction and the Necessary Conditions for Health
Related Articles
Sequential CD7 CAR T-Cell Therapy and Allogeneic HSCT without GVHD Prophylaxis | NEJM
Patients with relapsed or refractory hematologic cancers have a poor prognosis. Chimeric antigen receptor (CAR) T-cell therapy as a bridge to allogeneic hematopoietic stem-cell transplantation…
Exagamglogene Autotemcel for Severe Sickle Cell Disease | NEJM
Exagamglogene autotemcel (exa-cel) is a nonviral cell therapy designed to reactivate fetal hemoglobin synthesis by means of ex vivo clustered regularly interspaced short palindromic repeats…
Exagamglogene Autotemcel for Transfusion-Dependent β-Thalassemia | NEJM
Exagamglogene autotemcel (exa-cel) is a nonviral cell therapy designed to reactivate fetal hemoglobin synthesis through ex vivo clustered regularly interspaced short palindromic repeats (CRISPR)–Ca…
A Cell-free DNA Blood-Based Test for Colorectal Cancer Screening | NEJM
Original Article from The New England Journal of Medicine — A Cell-free DNA Blood-Based Test for Colorectal Cancer Screening
Specificity of CRISPR-Cas9 Editing in Exagamglogene Autotemcel | NEJM
The autologous cellular therapy exagamglogene autotemcel is generated by editing an erythroid-specific enhancer of BCL11A. Could another site be edited unintentionally? This study gauged the…
Exagamglogene Autotemcel for Severe Sickle Cell Disease | NEJM
Exagamglogene autotemcel (exa-cel) is a nonviral cell therapy designed to reactivate fetal hemoglobin synthesis by means of ex vivo clustered regularly interspaced short palindromic repeats…
Exagamglogene Autotemcel for Transfusion-Dependent β-Thalassemia | NEJM
Exagamglogene autotemcel (exa-cel) is a nonviral cell therapy designed to reactivate fetal hemoglobin synthesis through ex vivo clustered regularly interspaced short palindromic repeats (CRISPR)–Ca…
Nutritional Support for Moderate-to-Late–Preterm Infants — A Randomized Trial | NEJM
Most moderate-to-late–preterm infants need nutritional support until they are feeding exclusively on their mother’s breast milk. Evidence to guide nutrition strategies for these infants is…
CAR as Booster to Launch Allogeneic Transplantation in Refractory Leukemia | NEJM
Chimeric antigen receptor (CAR) T-cell therapies have revolutionized the treatment landscape for patients with relapsed or refractory B-cell lymphoid cancers.1 With studies showing that more…
Sequential CD7 CAR T-Cell Therapy and Allogeneic HSCT without GVHD Prophylaxis | NEJM
Patients with relapsed or refractory hematologic cancers have a poor prognosis. Chimeric antigen receptor (CAR) T-cell therapy as a bridge to allogeneic hematopoietic stem-cell transplantation…